Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 25;15(5):1046.
doi: 10.3390/v15051046.

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen

Valentina Iannone  1 , Rosa Anna Passerotto  1 , Francesco Lamanna  1 , Rebecca Jo Steiner  1 , Francesca Lombardi  2 , Pierluigi Francesco Salvo  1 , Alex Dusina  2 , Damiano Farinacci  3 , Alberto Borghetti  2 , Simona Di Giambenedetto  1   2 , Arturo Ciccullo  4
Affiliations

Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen

Valentina Iannone et al. Viruses. .

Abstract

Thanks to the modern ARV regimens and the fact that the morbidity and mortality of metabolic syndrome increases with age, clinicians are continuously researching effective and safe antiretroviral regimens with low impact on the lipid profile. Doravirine (DOR) is the latest non-nucleoside reverse-transcriptase inhibitor (NNRTI) that shows long-term safety and tolerability and a favorable lipid profile. The aim of this study is to assess the impact of DOR-based three-drug regimens on the lipid profile in clinical practice. We retrospectively analyzed a cohort of 38 treatment-experienced, virologically suppressed people living with HIV (PLWH) switching to this regimen, following the eligibility criteria. We carried out comparison analysis of immunological and metabolic parameters between baseline and 48 weeks of follow up. In our cohort of treatment-experienced, virologically suppressed PLWH, three-drug regimens with DOR showed good efficacy and a positive profile on lipid metabolism at 48 weeks of follow up.

Keywords: NNRTI; cardiovascular risk; doravirine; dyslipidemia; low density lipoprotein; metabolic syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Vargas-Pacherrez D., Cotrim H.P., Pires L., Cunha V., Coelho V., Brites C., Daltro C. Metabolic Syndrome in HIV-patients in Antiretroviral Therapy. Curr. HIV Res. 2020;18:388–395. doi: 10.2174/1570162X18666200609115615. - DOI - PubMed
    1. Sapuła M., Suchacz M., Załęski A., Wiercińska-Drapało A. Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review. Viruses. 2022;14:122. doi: 10.3390/v14010122. - DOI - PMC - PubMed
    1. Hsue P.Y., Hunt P.W., Schnell A., Kalapus S.C., Hoh R., Ganz P., Martin J.N., Deeks S.G. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059–1067. doi: 10.1097/QAD.0b013e32832b514b. - DOI - PMC - PubMed
    1. European AIDS Clinical Society EACS Guidelines Version 11.0. [(accessed on 15 September 2022)]; Available online: https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf.
    1. Soulie C., Santoro M.M., Charpentier C., Storto A., Paraskevis D., Di Carlo D., Gennari W., Sterrantino G., Zazzi M., Perno C.F., et al. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. J. Antimicrob. Chemother. 2019;74:614–617. doi: 10.1093/jac/dky464. - DOI - PubMed